Manuel Hidalgo, M.D., Ph.D., Joins ACLARA BioSciences Scientific Advisory Board
October 27 2004 - 9:01AM
PR Newswire (US)
Manuel Hidalgo, M.D., Ph.D., Joins ACLARA BioSciences Scientific
Advisory Board Another Distinguished Oncologist Highlights
Company's Advancements in Protein-Based Diagnostics MOUNTAIN VIEW,
Calif., Oct. 27 /PRNewswire-FirstCall/ -- ACLARA BioSciences
(NASDAQ:ACLA) announced that Manuel Hidalgo, M.D., Ph.D., has
joined its Scientific Advisory Board. Dr. Hidalgo is an Associate
Professor of Oncology and Co-Director of the Drug Development
Program at the Sidney Kimmel Comprehensive Cancer Center, Johns
Hopkins University School of Medicine in Baltimore, Maryland. Dr.
Hidalgo is considered a leading researcher in the development of
targeted therapies for the treatment of cancer in patients with
solid tumors. His research focuses on optimizing the clinical
development of novel treatments by measuring target receptor and
molecular anomalies, as well as analyzing the biological activity
in tumor and normal tissues of patients treated with specific
therapies. Dr. Hidalgo is the Principal Investigator in four new
clinical studies started within the last year at the Drug
Development Program at the Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins University School of Medicine. "I'm excited
to join ACLARA's Scientific Advisory Board as their technology and
approach offers a unique advantage in its ability to identify and
measure proteins with a high degree of sensitivity from solid
tissue samples." He continues, "While genomic approaches provide
insight, it is proteins and the interaction between proteins that
characterize particular types of cancer. By providing a sensitive
and robust way to quantify the relationship between a specific
tumor and protein interactions, ACLARA's technology is uniquely
suited to become a clinical test for physicians to deliver truly
personalized medicine to their patients." Dr. Hidalgo received his
M.D. from the University Navarra Medical School in Pamplona, Spain,
and his Ph.D. in Infectious Diseases in Cancer from the University
of Autonoma in Madrid, Spain. In 1997, he began his career as a
clinical research fellow at the Cancer Therapy and Research Center
in San Antonio, Texas, where he participated in the EORTC/NCI
Exchange Fellowship and AACR Young Investigator Fellowship in
Clinical Research. He worked as both an Assistant Professor of
Medicine at the University of Texas Health Science Center and as a
clinical investigator at the Cancer Therapy and Research Center. In
addition to publishing several peer-reviewed scientific papers, Dr.
Hidalgo has received numerous honors for his work, including the
2001 American Society of Clinical Oncology Career Development Award
According to ACLARA Chief Executive Officer Thomas Klopack, "We are
very excited to have another leading physician, who is so involved
with oncology and targeted therapies research, join our advisory
board. We anticipate that Dr. Hidalgo's input and expertise will
help ACLARA establish the eTag System as a robust clinical test
that allows physicians to understand which targeted treatment, or
combination of treatments, will be most effective in combating
their patient's cancer." ACLARA's Scientific Advisory Board now
comprises eight world-renowned physicians and researchers. In
addition to Dr. Hidalgo they include: David B. Agus, M.D., Research
Director at the Louis Warschaw Prostate Cancer Center at
Cedars-Sinai Medical Center and Assistant Professor of Medicine at
UCLA, Carlos L. Arteaga, M.D., Professor of Medicine and Cancer
Biology and Director of the Breast Cancer Research Program of the
Vanderbilt-Ingram Cancer Center at Vanderbilt University School of
Medicine, Jose Baselga, M.D., Professor of Medicine at the
Universidad Autonoma de Barcelona and the Scientific Chairman of
the Spanish Breast Cancer cooperative group SOLTI, Roy Herbst,
M.D., Ph.D., Chief of the Section of Thoracic Oncology and
Associate Professor at the University of Texas M. D. Anderson
Cancer Center in Houston, PJ Utz, M.D., Assistant Professor at the
Division of Rheumatology and Immunology at the Center for Clinical
Immunology at the Stanford University School of Medicine, John
Weinstein, M.D., Ph.D., Principal Investigator at the Laboratory of
Molecular Pharmacology within the National Cancer Institute's
Center for Cancer Research and Owen N. Witte, M.D., Professor of
Microbiology, Immunology and Molecular Genetics at UCLA. About the
eTag System The ability of the eTag System to identify
difficult-to-detect protein complexes in patient samples can
provide unique insights to the likelihood of an individual patient
to respond to specific therapies. In addition, since ACLARA's eTag
System requires only small amounts of biological material, and have
been shown to work in formalin-fixed paraffin-embedded tissue
sections (the standard format in pathology laboratories), both
retrospective and prospective analysis of clinical samples can be
performed. To further validate its eTag System, ACLARA is
correlating its test results with patient response data and outcome
information to demonstrate the assays' predictive power. Currently,
ACLARA is conducting studies with several clinical collaborators
based on the retrospective study of tissue samples from patients
participating in clinical trials for new drugs as well as from
those being treated with approved therapies. About ACLARA Founded
in 1995, ACLARA is a biotechnology company working to provide
physicians and researchers products and services to make
personalized medicine a reality through its protein-based assay
technology -- the eTag(TM) System. ACLARA is dedicated to unlocking
the power of pathway biology to accelerate the development of
next-generation targeted therapeutics, recognizing the most
appropriate patients for approved therapies and identifying the
highly-specific, protein-based biomarkers that will enable
physicians to create truly personalized treatment regimens for
patients suffering from cancer and other life-threatening
disorders. ACLARA is commercializing its proprietary eTag System to
enhance and accelerate drug discovery research and the preclinical
and clinical development of targeted therapeutics. ACLARA's
technology may also enable the development of highly-specific,
protein-based diagnostics capable of providing physicians with a
powerful tool for creating personalized treatment regimens for
patients suffering from serious and difficult-to-treat cancers. For
more information on ACLARA please visit the Company's web site at
http://www.aclara.com/. Forward-Looking Statements All statements
in this news release that are not historical are forward-looking
statements within the meaning of the Securities Exchange Act of
1934 as amended. Such forward-looking statements are subject to
factors that could cause actual results to differ materially for
ACLARA from those projected. Those factors include risks and
uncertainties relating to the performance of our products,
anticipated progress in commercialization of our eTag(TM) assay
system; the potential for use of our eTag assays in clinical
development programs; the potential for use of our eTag assays as
diagnostic tests; our ability to successfully conduct clinical
studies and the results obtained from those studies; our ability to
establish reliable, high-volume operations at commercially
reasonable costs; expected reliance on a few customers for the
majority of our revenues; actual market acceptance of our products
and adoption of our technological approach and products by
pharmaceutical and biotechnology companies; our estimate of the
size of our markets; our estimates of the levels of demand for our
products; our ability to develop organizational capabilities
suitable for the further development and commercialization of our
eTag assays; the ultimate validity and enforceability of our patent
applications and patents; the possible infringement of the
intellectual property of others; technological approaches of ACLARA
and our competitors; our pending merger with ViroLogic, Inc.,
including the risk that the closing conditions or the merger may
not be satisfied and the merger may not be completed, and costs
related to the proposed merger; and other risk factors identified
in our Form 10-Q for the quarter ended June 30, 2004 and the Joint
Proxy/Prospectus related to the proposed merger with ViroLogic as
filed with the Securities and Exchange Commission. Trademarks
ACLARA BioSciences is a registered trademark, and eTag and the
ACLARA logo are trademarks of ACLARA BioSciences, Inc. DATASOURCE:
ACLARA BioSciences, Inc. CONTACT: investors, Alfred Merriweather,
VP, Finance and CFO of ACLARA BioSciences, Inc., +1-650-210-1200,
or ; or media, Jennifer Viera of Schwartz Communications,
+1-781-684-0770, or , for ACLARA BioSciences, Inc. Web site:
http://www.aclara.com/
Copyright
Aclara Biosciences (NASDAQ:ACLA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Aclara Biosciences (NASDAQ:ACLA)
Historical Stock Chart
From Aug 2023 to Aug 2024